ES2609813T3 - Antígeno nuevo asociado con la neovasculatura de metástasis tumorales - Google Patents

Antígeno nuevo asociado con la neovasculatura de metástasis tumorales Download PDF

Info

Publication number
ES2609813T3
ES2609813T3 ES12195343.4T ES12195343T ES2609813T3 ES 2609813 T3 ES2609813 T3 ES 2609813T3 ES 12195343 T ES12195343 T ES 12195343T ES 2609813 T3 ES2609813 T3 ES 2609813T3
Authority
ES
Spain
Prior art keywords
antibody
domain
amino acid
acid sequence
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12195343.4T
Other languages
English (en)
Spanish (es)
Inventor
Dario Neri
Jascha Rybak
Christoph Rösli
Alessandra Villa
Giovanni Neri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philogen SpA
Original Assignee
Philogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen SpA filed Critical Philogen SpA
Application granted granted Critical
Publication of ES2609813T3 publication Critical patent/ES2609813T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
ES12195343.4T 2007-04-02 2008-03-31 Antígeno nuevo asociado con la neovasculatura de metástasis tumorales Active ES2609813T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90958007P 2007-04-02 2007-04-02
US909580P 2007-04-02
US94856407P 2007-07-09 2007-07-09
US948564P 2007-07-09

Publications (1)

Publication Number Publication Date
ES2609813T3 true ES2609813T3 (es) 2017-04-24

Family

ID=39791007

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12195343.4T Active ES2609813T3 (es) 2007-04-02 2008-03-31 Antígeno nuevo asociado con la neovasculatura de metástasis tumorales
ES08737486T Active ES2402171T3 (es) 2007-04-02 2008-03-31 El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08737486T Active ES2402171T3 (es) 2007-04-02 2008-03-31 El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales

Country Status (12)

Country Link
US (5) US8263041B2 (enExample)
EP (2) EP2142567B1 (enExample)
JP (2) JP5221641B2 (enExample)
KR (1) KR101515243B1 (enExample)
CN (2) CN103275220B (enExample)
AU (1) AU2008234615B2 (enExample)
BR (1) BRPI0809989B8 (enExample)
CA (1) CA2682851C (enExample)
EA (2) EA018985B1 (enExample)
ES (2) ES2609813T3 (enExample)
MX (1) MX2009010639A (enExample)
WO (1) WO2008120101A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817005B2 (ja) 1990-06-29 1998-10-27 スズキ株式会社 エンジン用オーバヒート検出装置
EA018985B1 (ru) 2007-04-02 2013-12-30 Филоджен С.П.А. Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
JP5204228B2 (ja) * 2007-07-25 2013-06-05 フィロゲン エスピーエー 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原
PT2209805T (pt) 2007-10-30 2017-11-14 Philogen Spa Um antigénio associado a artrite reumatoide
CA2748291A1 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Cancer treatment
US9527907B2 (en) 2009-01-07 2016-12-27 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
ES2712997T3 (es) 2009-08-05 2019-05-17 Philogen Spa Selección como diana de neovasculatura de médula ósea
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
JP5548872B2 (ja) * 2010-08-26 2014-07-16 株式会社島津製作所 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法
EP2621535A1 (en) 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
CA2842053C (en) 2011-07-27 2018-01-16 Philogen S.P.A. Il-12 immunoconjugate
SI2903629T1 (sl) 2012-10-03 2019-09-30 Philogen S.P.A. Konjugat protitelesa za uporabo pri zdravljenju vnetnih črevesnih bolezni
BR112016013641A2 (pt) 2013-12-12 2017-08-08 Umc Utrecht Holding Bv Moléculas tipo imunoglobulina direcionadas contra fibronectina-eda
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
ES2778430T3 (es) 2015-07-16 2020-08-10 Philogen Spa Inmunoconjugados de IL22
JP7039577B2 (ja) 2016-10-17 2022-03-22 ファイザー・インク 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CA3065153C (en) 2017-06-07 2023-09-05 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
WO2020247973A1 (en) * 2019-06-03 2020-12-10 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
PH12022550348A1 (en) 2019-08-15 2022-12-12 Janssen Biotech Inc Materials and methods for improved single chain variable fragments
WO2022018126A1 (en) 2020-07-22 2022-01-27 Philogen S.P.A. Treatment of pulmonary hypertension
CN114350518B (zh) * 2022-01-19 2023-01-13 广东乾晖生物科技有限公司 仿生肝微流控细胞培养-药物筛选芯片
US20250197485A1 (en) 2022-03-17 2025-06-19 Universitätsklinikum Jena Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
FI892197A7 (fi) * 1989-05-08 1990-11-09 Locus Oy Foerfarande foer detektering av tumoerer.
US5420012A (en) * 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992017604A1 (fr) * 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anticorps monoclonal anti-eda
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
PT1137941E (pt) 1998-12-10 2009-10-15 Brystol Myers Squibb Company Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação
CA2399866C (en) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US20030152572A1 (en) 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
AU1218202A (en) 2000-09-07 2002-03-22 Schering Ag Receptor in the ED<sub>b</sub> fibronectin domain
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7560095B2 (en) 2003-04-22 2009-07-14 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
US8038983B2 (en) 2003-07-29 2011-10-18 Immunomedics, Inc. Fluorinated carbohydrate conjugates
AU2005280528B2 (en) * 2004-07-30 2010-12-23 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
SI1817345T1 (sl) 2004-11-09 2009-10-31 Philogen Spa Protitelesa proti tenascinu-C
CA2607954A1 (en) 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
EA018985B1 (ru) * 2007-04-02 2013-12-30 Филоджен С.П.А. Новый антиген, ассоциированный с новообразованными сосудами опухолевых метастазов
JP5204228B2 (ja) * 2007-07-25 2013-06-05 フィロゲン エスピーエー 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原
PT2209805T (pt) * 2007-10-30 2017-11-14 Philogen Spa Um antigénio associado a artrite reumatoide
US9527907B2 (en) * 2009-01-07 2016-12-27 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
EP2621535A1 (en) * 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
CA2842053C (en) * 2011-07-27 2018-01-16 Philogen S.P.A. Il-12 immunoconjugate
EP2988784A1 (en) * 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
CA2910044A1 (en) * 2013-04-26 2014-10-30 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
AU2008234615B2 (en) 2013-10-10
CN103275220B (zh) 2016-01-20
HK1140217A1 (en) 2010-10-08
EP2653478A1 (en) 2013-10-23
AU2008234615A1 (en) 2008-10-09
ES2402171T3 (es) 2013-04-29
US9181347B2 (en) 2015-11-10
CA2682851A1 (en) 2008-10-09
EP2142567B1 (en) 2013-01-16
WO2008120101A2 (en) 2008-10-09
US20160083461A1 (en) 2016-03-24
US8481684B2 (en) 2013-07-09
US8263041B2 (en) 2012-09-11
BRPI0809989A2 (pt) 2015-09-29
CA2682851C (en) 2017-01-17
US20130266511A1 (en) 2013-10-10
JP5221641B2 (ja) 2013-06-26
CN101687923B (zh) 2013-06-19
US20130280759A1 (en) 2013-10-24
JP2010523541A (ja) 2010-07-15
US20130040361A1 (en) 2013-02-14
US20100247541A1 (en) 2010-09-30
JP5840631B2 (ja) 2016-01-06
CN101687923A (zh) 2010-03-31
EP2142567A2 (en) 2010-01-13
EA200970909A1 (ru) 2010-10-29
EA018985B1 (ru) 2013-12-30
WO2008120101A3 (en) 2008-12-11
BRPI0809989B8 (pt) 2021-05-25
US9896503B2 (en) 2018-02-20
EP2653478B1 (en) 2016-10-05
CN103275220A (zh) 2013-09-04
KR20100016094A (ko) 2010-02-12
HK1184794A1 (zh) 2014-01-30
KR101515243B1 (ko) 2015-04-24
MX2009010639A (es) 2009-10-23
EA036322B1 (ru) 2020-10-26
JP2013121353A (ja) 2013-06-20
EA201301224A1 (ru) 2014-07-30
BRPI0809989B1 (pt) 2019-10-08

Similar Documents

Publication Publication Date Title
ES2609813T3 (es) Antígeno nuevo asociado con la neovasculatura de metástasis tumorales
AU2020203143B2 (en) Modified antibody compositions, methods of making and using thereof
ES2632748T3 (es) Anticuerpos anti-C4.4a y usos de los mismos
JP6335796B2 (ja) Ｃｄｉｍ結合タンパク質及びその使用
CN111148759B (zh) 结合至纤维连接蛋白b结构域的蛋白
CN111234020B (zh) 一种bcma结合蛋白及其制备方法和应用
EP3970798A1 (en) Sars-cov-2-nanobodies
US12492249B2 (en) Antibodies and use thereof
Haus‐Cohen et al. Disruption of P‐glycoprotein anticancer drug efflux activity by a small recombinant single‐chain Fv antibody fragment targeted to an extracellular epitope
CN107531795A (zh) Pcsk9抗体、其抗原结合片段及其医药用途
DK3166660T3 (en) SUBSTANCES AND PROCEDURES FOR USE IN PREVENTION AND / OR TREATMENT OF HUNTINGTON&#39;S DISEASE
WO2021169982A1 (zh) 靶向EpCAM的抗体及其制备和应用
CN107074925A (zh) 用于预防和/或治疗亨廷顿氏病的物质和方法
KR20250107848A (ko) 코트머단백질 복합체 서브유닛 베타2에 대한 항체
JP2017503176A (ja) 抗ｍｉｆ免疫組織化学的検査
CN115850458B (zh) 一种抗冠状病毒rbd蛋白的抗体、制备方法和应用
CN119912561B (zh) 一种抗s100蛋白的抗体及其应用
KR20200002190A (ko) 항 스핑고신-1-포스페이트 작용제, 이의 생산 방법, 및 이의 용도
WO2025122066A1 (en) Ddx3y specific binding domains
Van Fossen Employing Genetic Code Expansion Tools to Elucidate Disease Mechanisms and Generate New Therapeutics
HK40031847A (en) A bcma binding protein and method for preparation and application thereof
HK40031847B (en) A bcma binding protein and method for preparation and application thereof
EP3823994A1 (en) Novel systems for screening internalizing antibody and uses thereof
CN108727493A (zh) 抗Stathmin单克隆抗体及其用途
JP2016534734A (ja) 急性骨髄性白血病の診断のための抗体